The impact of multimorbidity on the effects of empagliflozin in chronic kidney disease (CKD): exploratory analyses from the EMPA-KIDNEY trial

被引：0
|
作者：
Mayne, Kaitlin [1 ]
机构：
[1] Univ Oxford, Nuffield Dept Populat Hlth, Richard Doll Bldg,Old Rd Campus, Oxford, England
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2024年 / 39卷
关键词：
D O I：
10.1093/ndt/gfae069.062
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
308
引用
收藏
页数：3
相关论文
共 50 条
  • [1] The impact of multimorbidity on the effects of empagliflozin in chronic kidney disease (CKD): exploratory analyses from the EMPA-KIDNEY trial
    Mayne, Kaitlin
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 : I112 - I114
  • [2] Effects of empagliflozin in patients with chronic kidney disease from Japan: exploratory analyses from EMPA-KIDNEY
    Nangaku, Masaomi
    Herrington, William G.
    Goto, Shinya
    Maruyama, Shoichi
    Kashihara, Naoki
    Ueki, Kohjiro
    Wada, Jun
    Watada, Hirotaka
    Nakashima, Eitaro
    Lee, Ryonfa
    Massey, Dan
    Mayne, Kaitlin J.
    Tomita, Aiko
    Haynes, Richard
    Hauske, Sibylle J.
    Kadowaki, Takashi
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2024, 28 (06) : 588 - 595
  • [3] Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial
    Mayne, Kaitlin J.
    Sardell, Rebecca J.
    Staplin, Natalie
    Judge, Parminder K.
    Zhu, Doreen
    Sammons, Emily
    Cherney, David Z., I
    Green, Jennifer B.
    Levin, Adeera
    Pontremoli, Roberto
    Hauske, Sibylle J.
    Emberson, Jonathan
    Preiss, David
    Landray, Martin J.
    Baigent, Colin
    Wanner, Christoph
    Haynes, Richard
    Herrington, William G.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2025, 40 (04) : 720 - 730
  • [4] Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial
    Judge, Parminder K.
    Staplin, Natalie
    Mayne, Kaitlin J.
    Wanner, Christoph
    Green, Jennifer B.
    Hauske, Sibylle J.
    Emberson, Jonathan R.
    Preiss, David
    Ng, Sarah Y. A.
    Roddick, Alistair J.
    Sammons, Emily
    Zhu, Doreen
    Hill, Michael
    Stevens, Will
    Wallendszus, Karl
    Brenner, Susanne
    Wallendszus, Karl
    Brenner, Susanne
    Cheung, Alfred K.
    Liu, Zhi-Hong
    Li, Jing
    Hooi, Lai Seong
    Liu, Wen Jiun
    Kadowaki, Takashi
    Nangaku, Masaomi
    Levin, Adeera
    Cherney, David
    Maggioni, Aldo P.
    Pontremoli, Roberto
    Deo, Rajat
    Goto, Shinya
    Rossello, Xavier
    Tuttle, Katherine R.
    Steubl, Dominik
    Massey, Dan
    Landray, Martin J.
    Baigent, Colin
    Haynes, Richard
    Herrington, William G.
    LANCET DIABETES & ENDOCRINOLOGY, 2024, 12 (01): : 51 - 60
  • [5] Empagliflozin and Cardiovascular Outcomes in Patients With Chronic Kidney Disease: The EMPA-KIDNEY Trial
    Preiss, David
    Herrington, William
    Haynes, Richard
    CIRCULATION, 2022, 146 (25) : E577 - E577
  • [6] Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the EMPA-KIDNEY trial
    Staplin, Natalie
    Haynes, Richard
    Judge, Parminder K.
    Wanner, Christoph
    Green, Jennifer B.
    Emberson, Jonathan R.
    Preiss, David
    Mayne, Kaitlin J.
    Ng, Sarah Y. A.
    Sammons, Emily
    Zhu, Doreen
    Hill, Michael
    Stevens, Will
    Wallendszus, Karl
    Brenner, Susanne
    Cheung, Alfred K.
    Liu, Zhi-Hong
    Li, Jing
    Hooi, Lai Seong
    Liu, Wen
    Kadowaki, Takashi
    Nangaku, Masaomi
    Levin, Adeera
    Cherney, David
    Maggioni, Aldo P.
    Pontremoli, Roberto
    Deo, Rajat
    Goto, Shinya
    Rossello, Xavier
    Tuttle, Katherine R.
    Steubl, Dominik
    Petrini, Michaela
    Seide, Svenja
    Landray, Martin J.
    Baigent, Colin
    Herrington, William G.
    LANCET DIABETES & ENDOCRINOLOGY, 2024, 12 (01): : 39 - 50
  • [7] EFFECTS OF EMPAGLIFLOZIN ON FLUID OVERLOAD IN CHRONIC KIDNEY DISEASE: AN EMPA-KIDNEY BIOIMPEDANCE SUBSTUDY
    Mayne, Kaitlin
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 : I49 - I50
  • [8] THE IMPACT OF BASELINE FRAILTY, MULTIMORBIDITY, POLYPHARMACY AND HEALTH-RELATED QUALITY OF LIFE ON THE EFFECTS OF EMPAGLIFLOZIN: POST-HOC ANALYSES FROM THE EMPA-KIDNEY TRIAL
    O'Hara, Daniel Vincent
    NEPHROLOGY, 2024, 29 : 29 - 30
  • [9] Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial (vol 12, pg 39, 2024)
    Staplin, N.
    LANCET DIABETES & ENDOCRINOLOGY, 2024, 12 (11): : e20 - e20
  • [10] Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the EMPA-KIDNEY trial. (vol 12, pg 39, 2024)
    Staplin, N.
    LANCET DIABETES & ENDOCRINOLOGY, 2024, 12 (03): : e16 - e16
12345